CASI Pharmaceuticals (CASI) Downgraded by Zacks Investment Research to Hold

CASI Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  CASI Pharmaceuticals Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of CASI Pharmaceuticals traded up $0.02 on Wednesday, reaching $1.19. 1384966 shares of the stock traded hands, compared to its average volume of 3120429. Shares of CASI Pharmaceuticals were trading at $1.19 on Wednesday. The firm’s 50 day moving average is $1.34 and its 200 day moving average is $1.92.CASI Pharmaceuticals has a 12 month low of $1.15 and a 12 month high of $3.90. While on yearly highs and lows, CASI Pharmaceuticals’s today has traded high as $1.21 and has touched $1.15 on the downward trend. See More Analyst Rating at: RATING

CASI Pharmaceuticals Earnings and What to expect: 

CASI Pharmaceuticals last released its earnings results on August 11th, 2021. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.02. The business had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.15 million. CASI Pharmaceuticals has generated ($0.43) earnings per share over the last year (($0.42) diluted earnings per share). Earnings for CASI Pharmaceuticals are expected to grow in the coming year, from ($0.26) to ($0.21) per share. CASI Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

Earnings for CASI Pharmaceuticals are expected to grow in the coming year, from ($0.26) to ($0.21) per share. The P/E ratio of CASI Pharmaceuticals is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of CASI Pharmaceuticals is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. CASI Pharmaceuticals has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

CASI Pharmaceuticals (CASI) Moving Average Technical Analysis

5 day Moving Average is $1.18 And 5 day price change is $0.03 (2.59%)  with average volume for 5 day average is 1,374,680. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $1.23 and 20 day price change is -$0.29 (-19.59%) and average 20 day moving volume is 3,102,585. 50 day moving average is $1.34  and 50 day price change is -$0.01 ( -0.83%)  and with average volume for 50 days is : 2,852,906. 200 day moving average is $1.92  and 200 day price change is -$1.73 (-59.25%)  and with average volume for 200 days is : 1,626,917.

Other owners latest trading in CASI Pharmaceuticals :

  • On 8/26/2021 shares held by Y Intercept Hong Kong Ltd were 16,246 which equates to market value of $25K and appx 0.00% owners of CASI Pharmaceuticals
  • On 8/25/2021 shares held by Marshall Wace LLP were 223,709 which equates to market value of $0.35M and appx 0.00% owners of CASI Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 43,285 which equates to market value of $68K and appx 0.00% owners of CASI Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 33.42% for CASI Pharmaceuticals

See More Analyst Rating at: RATING